Association of serum homocysteine, folate, and vitamin B12 and mood following the Swank and Wahls elimination dietary interventions in relapsing-remitting multiple sclerosis: Secondary analysis of the WAVES trial.

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in the context of multiple sclerosis in this randomized controlled trial publication.

This study aimed to evaluate the impact of the low-saturated fat (Swank) and modified Paleolithic elimination (Wahls) diets, along with a supplement regimen, on mood as assessed by Hospital Anxiety and Depression Scale (HADS), and Mental Health Inventory (MHI).

The secondary objective was to identify changes in serum levels of homocysteine, folate, and vitamin B12 and the association and mediation effects between their changes and HADS and MHI scores and their subscales among people with relapsing-remitting MS (RRMS).

HADS and MHI questionnaires were also completed by participants at the four study visits to assess symptoms of depression and anxiety, behavioral control and positive affect respectively.

Why It Was Studied

Depression and anxiety are common psychiatric comorbidities among people with multiple sclerosis (MS).

How the Study Was Run

The researchers set it up as a randomized and parallel-group study.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blood was drawn at four study visits spaced 12 weeks apart: (1) run-in, (2) baseline, (3) 12 weeks, and (4) 24 weeks.

Serum vitamin B12, folate, and homocysteine were analyzed.

What Was Measured

The subject headings attached to it are Vitamin B 12, Folic Acid, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting and Vitamins.

Author keywords: Depression, Homocysteine, Low-saturated fat diet, Modified Paleolithic elimination diet and Vitamin B(12).

What This Means in Plain Language

The paper is a randomized and parallel-group study of Cyanocobalamin (Vitamin B12) in people with multiple sclerosis.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Multiple sclerosis and related disorders), a journal based in Netherlands.

More context: the Cyanocobalamin (Vitamin B12) compound page, Multiple sclerosis research.